PRECIGEN INC (PGEN) Stock News

USA - NASDAQ:PGEN - US74017N1054 - Common Stock

3.48 USD

-0.38 (-9.84%)

Last: 9/25/2025, 7:38:21 PM

3.47 USD

-0.01 (-0.29%)

After Hours: 9/25/2025, 7:38:21 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

PGEN Latest News, Press Relases and Analysis

All

Press Releases

18 days ago - By: The Motley Fool - Mentions: AZN MLYS

These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts

22 days ago - By: Benzinga - Mentions: RZLV YDES URG ALKS ...

Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday

23 days ago - By: Precigen, Inc.

Precigen Announces Up to $125 Million Non-Dilutive Financing

a month ago - By: Zacks Investment Research - Mentions: INO CRMD KNSA

INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug

a month ago - By: Yahoo Finance

Citizens JMP Raises PT on Precigen from $6 to $8, Keeps Outperform Rating

a month ago - By: Precigen, Inc.

Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

a month ago - By: Benzinga - Mentions: NDSN OPEN BNC XYF ...

SelectQuote Posts Better-Than-Expected Results, Joins Nutex Health, NIO, MINISO Group And Other Big Stocks Moving Higher On Thursday

a month ago - By: Stocktwits - Mentions: IWMW

Precigen Stock Shot Through The Roof On Friday Morning – Here’s Why

a month ago - By: Yahoo Finance - Mentions: PFE LLY GBIO

Precigen wins immunotherapy approval; Pfizer sickle cell drug fails trial

a month ago - By: Precigen, Inc.

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis